Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs
Zoetis Inc. today announced that Health Canada has approved Lenivia® (izenivetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in dogs. Built on a decade of science and research, Lenivia is a new antibody therapy with a safety profile demonstrated in a nine-month field study where dogs receiving Lenivia experienced increased mobility and decreased pain after one injection. Lenivia effectively alleviates OA pain for three months with one injection through its novel binding properties to nerve growth factor (NGF), recognized as an important mediator of pain and inflammation.
Significance of OA Pain
Osteoarthritis is a common, chronic and progressive joint disease characterized by the inflammation and breakdown of joints, leading to pain and mobility issues. Although the disease cannot be cured, much can be done to alleviate the associated pain and improve quality of life. Nearly 40 percent of dogs of any age or size may be affected by OA pain1, 2, and chronic pain can negatively impact dogs’ movement, sleep, behavior and social relationships3.
“As the leader in animal health innovation and the groundbreaker in veterinary monoclonal antibodies, our scientists at Zoetis are committed to deeply understanding the unique species’ biology that drives the discovery and development that ultimately helps us meet our customers’ unmet medical needs,” said Rob Polzer, Ph.D., Executive Vice President and President, Research and Development at Zoetis. “Health Canada’s approval of Lenivia makes it the world’s first monoclonal antibody to alleviate OA pain in dogs for three months.”
Continued Innovation to Meet Medical Needs
Zoetis continues to advance care for animals around the globe with a robust pipeline fueled by lifecycle innovation, geographic expansion and disruptive innovation. Lenivia joins Librela® (bedinvetmab injection) in the company’s growing portfolio of OA pain products for dogs. Like Librela, Lenivia is a monoclonal antibody that targets NGF; however, Lenivia is designed to alleviate pain associated with OA for a longer period of time by binding to a different site on NGF.
“We are pleased to introduce Lenivia as our first long-acting therapy that alleviates OA pain in dogs, leading to improved quality of life and mobility. It also provides added convenience for pet owners who want to bring their dogs in for an injection once every three months,” said Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer and Head of Medical Affairs at Zoetis. “More than two years ago in Canada, we introduced the first monoclonal antibody therapy to alleviate pain associated with OA pain in dogs, and we look forward to providing veterinarians with another innovative tool to help them improve the quality of life for the animals in their care.”
About Lenivia
Lenivia is a monoclonal antibody therapy that binds to nerve growth factor to reduce NGF’s effects. Lenivia is indicated for the alleviation of pain associated with osteoarthritis in dogs. Lenivia is administered subcutaneously once every three months. Lenivia should not be used in dogs with known hypersensitivity to izenivetmab, or breeding, pregnant or lactating dogs, or dogs less than 12 months of age. The following clinical signs have been reported in dogs receiving Lenivia: balance problems, weakness or trouble standing, decreased appetite, vomiting or diarrhea, drinking more and urinating more.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees.
Source: www.zoetis.com
Comments
Tag
Related Articles
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment